This is a summary of the European public assessment report (EPAR) for Jevtana. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Jevtana.
Therapeutic Indication
### Therapeutic indication Jevtana in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone-refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
Therapeutic Area (MeSH)
ATC Code
L01CD
ATC Item
紫杉生物碱类
Pharmacotherapeutic Group
Antineoplastic agents
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| cabazitaxel | N/A | 卡巴他赛 |
EMA Name
Jevtana
Medicine Name
Jevtana
Aliases
N/A
